NASDAQ:KPTI Karyopharm Therapeutics (KPTI) Stock Price, News & Analysis → No Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for Free (From Hedgeye) (Ad) Free KPTI Stock Alerts $0.96 -0.01 (-1.31%) (As of 06/7/2024 08:52 PM ET) Add Compare Share Share Today's Range$0.93▼$0.9950-Day Range$0.93▼$1.5852-Week Range$0.62▼$2.42Volume1.75 million shsAverage Volume1.56 million shsMarket Capitalization$119.66 millionP/E RatioN/ADividend YieldN/APrice Target$4.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Karyopharm Therapeutics alerts: Email Address Karyopharm Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.60 Rating ScoreUpside/Downside399.9% Upside$4.80 Price TargetShort InterestBearish14.09% of Shares Sold ShortDividend StrengthN/ASustainability-1.11Upright™ Environmental ScoreNews Sentiment-0.10Based on 21 Articles This WeekInsider TradingSelling Shares$1.24 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.25) to ($0.90) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.42 out of 5 starsMedical Sector250th out of 903 stocksPharmaceutical Preparations Industry111th out of 426 stocks 3.3 Analyst's Opinion Consensus RatingKaryopharm Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageKaryopharm Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Karyopharm Therapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted14.09% of the outstanding shares of Karyopharm Therapeutics have been sold short.Short Interest Ratio / Days to CoverKaryopharm Therapeutics has a short interest ratio ("days to cover") of 13.6, which indicates bearish sentiment.Change versus previous monthShort interest in Karyopharm Therapeutics has recently increased by 2.27%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldKaryopharm Therapeutics does not currently pay a dividend.Dividend GrowthKaryopharm Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreKaryopharm Therapeutics has received a 71.09% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Other cancer medication", "Clinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Karyopharm Therapeutics is -1.11. Previous Next 2.2 News and Social Media Coverage News SentimentKaryopharm Therapeutics has a news sentiment score of -0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 21 news articles for Karyopharm Therapeutics this week, compared to 2 articles on an average week.Search Interest7 people have searched for KPTI on MarketBeat in the last 30 days. This is an increase of 40% compared to the previous 30 days.MarketBeat Follows2 people have added Karyopharm Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Karyopharm Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,244,993.00 in company stock.Percentage Held by InsidersOnly 4.30% of the stock of Karyopharm Therapeutics is held by insiders.Percentage Held by Institutions66.44% of the stock of Karyopharm Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Karyopharm Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Karyopharm Therapeutics are expected to grow in the coming year, from ($1.25) to ($0.90) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Karyopharm Therapeutics is -0.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Karyopharm Therapeutics is -0.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Karyopharm Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Traders AgencyHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942%, and 12,592% in 2020. Now their next one could be here.Click here to pay just $5 for a full year of Stealth Trades About Karyopharm Therapeutics Stock (NASDAQ:KPTI)Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.Read More KPTI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KPTI Stock News HeadlinesJune 9 at 5:30 AM | insidertrades.comDeepika Pakianathan Sells 231,548 Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) StockJune 6, 2024 | insidertrades.comInsider Selling: Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Director Sells 204,394 Shares of StockJune 10 at 4:48 AM | americanbankingnews.comKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Director Sells $449,322.24 in StockJune 9 at 3:24 AM | americanbankingnews.comKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Given Consensus Recommendation of "Moderate Buy" by AnalystsJune 5, 2024 | americanbankingnews.comBrokers Issue Forecasts for Karyopharm Therapeutics Inc.'s FY2025 Earnings (NASDAQ:KPTI)June 5, 2024 | americanbankingnews.comKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Director Deepika Pakianathan Sells 360,744 SharesJune 3, 2024 | prnewswire.comKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 3, 2024 | americanbankingnews.comKaryopharm Therapeutics (NASDAQ:KPTI) Given "Buy" Rating at HC WainwrightJune 1, 2024 | prnewswire.comKaryopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract UpdatesMay 29, 2024 | prnewswire.comKaryopharm to Participate at the Jefferies Global Healthcare ConferenceMay 23, 2024 | investorplace.comThe Next Novavax? 3 Biopharma Stocks to Buy Before They BoomMay 10, 2024 | seekingalpha.comKPTI Karyopharm Therapeutics Inc.May 10, 2024 | markets.businessinsider.comBuy Rating for Karyopharm Therapeutics: Debt Restructuring and Promising Xpovio Studies Drive Optimistic OutlookMay 10, 2024 | finance.yahoo.comKaryopharm Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagMay 9, 2024 | markets.businessinsider.comOptimistic Buy Rating for Karyopharm Therapeutics Amidst Financial Stability and Promising Clinical TrialsMay 9, 2024 | finance.yahoo.comKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Q1 2024 Earnings Call TranscriptMay 9, 2024 | finance.yahoo.comKaryopharm Therapeutics Inc (KPTI) Q1 2024 Earnings Call Transcript Highlights: Navigating ...May 8, 2024 | finance.yahoo.comQ1 2024 Karyopharm Therapeutics Inc Earnings CallMay 8, 2024 | finanznachrichten.deKaryopharm Therapeutics Inc.: Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company ProgressMay 8, 2024 | finance.yahoo.comKaryopharm Therapeutics Reports Q1 2024 Financial Results: A Detailed ReviewMay 8, 2024 | markets.businessinsider.comKaryopharm Therapeutics Inc. Q1 Loss increases, but beats estimatesMay 8, 2024 | prnewswire.comKaryopharm to Participate at the 2024 RBC Capital Markets Global Healthcare ConferenceMay 8, 2024 | investorplace.comKPTI Stock Earnings: Karyopharm Therapeutics Beats EPS, Misses Revenue for Q1 2024May 8, 2024 | prnewswire.comKaryopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company ProgressMay 8, 2024 | prnewswire.comKaryopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029See More Headlines Receive KPTI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Karyopharm Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today6/09/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:KPTI CUSIPN/A CIK1503802 Webwww.karyopharm.com Phone(617) 658-0600FaxN/AEmployees325Year FoundedN/APrice Target and Rating Average Stock Price Target$4.80 High Stock Price Target$8.00 Low Stock Price Target$3.00 Potential Upside/Downside+399.9%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-143,100,000.00 Net Margins-104.18% Pretax Margin-103.94% Return on EquityN/A Return on Assets-57.80% Debt Debt-to-Equity RatioN/A Current Ratio3.04 Quick Ratio2.99 Sales & Book Value Annual Sales$146.03 million Price / Sales0.82 Cash FlowN/A Price / Cash FlowN/A Book Value($1.19) per share Price / Book-0.81Miscellaneous Outstanding Shares124,620,000Free Float119,258,000Market Cap$119.66 million OptionableOptionable Beta0.25 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Richard A. Paulson M.B.A. (Age 57)President, CEO & Director Comp: $1.43MMs. Sohanya Cheng M.B.A. (Age 41)Executive VP & Chief Commercial Officer Comp: $742.95kMr. Stuart PoultonExecutive VP & Chief Development OfficerDr. Reshma Rangwala M.D. (Age 46)Ph.D., Executive VP, Chief Medical Officer & Head of Research Comp: $777.32kDr. Mansoor Raza Mirza M.D. (Age 63)Clinical Consultant, Member of Scientific Advisory Board & Independent Director Comp: $150kDr. Sharon Shacham M.B.A. (Age 54)Ph.D., Co-Founder & Chairman of Scientific Advisory Board Comp: $1.4MMr. Cameron Peters (Age 64)Vice President of Finance, Assistant Treasurer & Principal Accounting Officer Ms. Elhan Webb C.F.A.Senior Vice President of Investor RelationsMr. Michael J. Mano J.D. (Age 47)Senior VP, General Counsel & Secretary Comp: $625.08kMr. James Accumanno J.D.Chief Compliance OfficerMore ExecutivesKey CompetitorsBioXcel TherapeuticsNASDAQ:BTAICOMPASS PathwaysNASDAQ:CMPSAC ImmuneNASDAQ:ACIUCorbus PharmaceuticalsNASDAQ:CRBPALX OncologyNASDAQ:ALXOView All CompetitorsInsiders & InstitutionsDeepika PakianathanSold 231,548 sharesTotal: $219,970.60 ($0.95/share)Deepika PakianathanSold 468,044 sharesTotal: $449,322.24 ($0.96/share)Richard A PaulsonSold 3,592 sharesTotal: $3,556.08 ($0.99/share)Michael MasonSold 652 sharesTotal: $645.48 ($0.99/share)Deepika PakianathanSold 360,744 sharesTotal: $360,744.00 ($1.00/share)View All Insider TransactionsView All Institutional Transactions KPTI Stock Analysis - Frequently Asked Questions Should I buy or sell Karyopharm Therapeutics stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Karyopharm Therapeutics in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" KPTI shares. View KPTI analyst ratings or view top-rated stocks. What is Karyopharm Therapeutics' stock price target for 2024? 5 Wall Street analysts have issued 12 month price targets for Karyopharm Therapeutics' stock. Their KPTI share price targets range from $3.00 to $8.00. On average, they predict the company's share price to reach $4.80 in the next year. This suggests a possible upside of 399.9% from the stock's current price. View analysts price targets for KPTI or view top-rated stocks among Wall Street analysts. How have KPTI shares performed in 2024? Karyopharm Therapeutics' stock was trading at $0.8650 at the beginning of the year. Since then, KPTI stock has increased by 11.0% and is now trading at $0.9602. View the best growth stocks for 2024 here. When is Karyopharm Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024. View our KPTI earnings forecast. How were Karyopharm Therapeutics' earnings last quarter? Karyopharm Therapeutics Inc. (NASDAQ:KPTI) announced its quarterly earnings results on Wednesday, May, 8th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.33) by $0.01. The company had revenue of $33.13 million for the quarter, compared to analysts' expectations of $35.02 million. What guidance has Karyopharm Therapeutics issued on next quarter's earnings? Karyopharm Therapeutics updated its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $140.0 million-$160.0 million, compared to the consensus revenue estimate of $146.5 million. What is Michael Kauffman's approval rating as Karyopharm Therapeutics' CEO? 31 employees have rated Karyopharm Therapeutics Chief Executive Officer Michael Kauffman on Glassdoor.com. Michael Kauffman has an approval rating of 83% among the company's employees. What other stocks do shareholders of Karyopharm Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Karyopharm Therapeutics investors own include NVIDIA (NVDA), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Alibaba Group (BABA), Micron Technology (MU), Invitae (NVTA), Advanced Micro Devices (AMD), AbbVie (ABBV), Inovio Pharmaceuticals (INO) and Bristol-Myers Squibb (BMY). Who are Karyopharm Therapeutics' major shareholders? Karyopharm Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (7.16%), GSA Capital Partners LLP (1.12%), Ikarian Capital LLC (0.35%) and Simplicity Wealth LLC (0.04%). Insiders that own company stock include Deepika Pakianathan, Garen G Bohlin, Jatin Shah, Michael Kauffman, Michael Mano, Michael Mason, Reshma Rangwala, Richard A Paulson, Sharon Shacham, Sohanya Roshan Cheng, Stephen Mitchener and Stuart Poulton. View institutional ownership trends. How do I buy shares of Karyopharm Therapeutics? Shares of KPTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:KPTI) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersYou won't believe what Citigroup just did to it's depositorsThe FEDNOW Biden Dollar ends cash in a matter of WEEKS Stumbling Biden's dollar next phases begins Oct 21st...American Alternative | SponsoredIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredRSVP: Charles Payne’s Cash Flow WorkshopDid you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? ...Unstoppable Prosperity | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Karyopharm Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Karyopharm Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.